
News|Videos|December 17, 2024
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Author(s)David S. Hong, MD
Dr. David S. Hong presents the preliminary Phase 1 results on RMC-9805, a first-in-class, oral, RAS(ON) G12D-selective inhibitor, highlighting its promising safety, pharmacokinetics, and early antitumor activity in patients with KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC), with further dose optimization and combination studies underway.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































